- Home
- ZLAB vs IMAX Comparison
ZLAB vs IMAX Comparison
Compare ZLAB & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZLAB | IMAX |
|---|---|---|
| Founded | 2013 | 1967 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | 2017 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | IMAX |
|---|---|---|
| Price | $18.31 | $48.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $49.60 | $44.50 |
| AVG Volume (30 Days) | 714.0K | ★ 1.4M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | 31.25 |
| EPS | N/A | ★ 0.35 |
| Revenue | ★ $460,156,000.00 | $410,212,000.00 |
| Revenue This Year | $9.75 | $9.79 |
| Revenue Next Year | $26.03 | $7.51 |
| P/E Ratio | ★ N/A | $134.44 |
| Revenue Growth | 15.33 | ★ 16.47 |
| 52 Week Low | $15.96 | $24.20 |
| 52 Week High | $39.64 | $47.13 |
Technical Indicators
Market Signals| Indicator | ZLAB | IMAX |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 71.63 |
| Support Level | $16.84 | $36.25 |
| Resistance Level | $19.55 | N/A |
| Average True Range (ATR) | 0.76 | 1.77 |
| MACD | -0.25 | 0.96 |
| Stochastic Oscillator | 4.64 | 94.70 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
About IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.